Shree Hari International Llc

Shree Hari International LLC is a U.S.-based pharmaceutical importer specializing in the acquisition of finished pharmaceutical formulations from India. Operating as a buyer, the company plays a pivotal role in sourcing and distributing a diverse range of pharmaceutical products within the United States market. Headquartered in East Brunswick, New Jersey, Shree Hari International LLC is an independent entity without a publicly known parent company. Its primary function involves importing finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, thereby contributing to the availability of various therapeutic options in the U.S.

While specific details about Shree Hari International LLC's warehouse locations and logistics capabilities are not publicly disclosed, the company's operations suggest a well-established distribution network within the United States. The importation of pharmaceutical products from India indicates a reliance on efficient logistics to manage the complexities of international shipping, customs clearance, and compliance with U.S. regulations. The company's geographic coverage likely spans key U.S. regions, ensuring timely delivery to meet market demand.

In the U.S. pharmaceutical supply chain, Shree Hari International LLC functions as a pharmaceutical importer, sourcing finished pharmaceutical formulations from Indian manufacturers. By facilitating the entry of these products into the U.S. market, the company serves as a critical intermediary between Indian pharmaceutical producers and U.S. distributors, wholesalers, and healthcare providers. This role is essential in diversifying the pharmaceutical supply and providing access to a broader range of medications.

Shree Hari International LLC's sourcing strategy exhibits a high degree of concentration, with a significant majority of its imports originating from Elysium Pharmaceuticals Limited. This single-source dependency may present risks, such as supply chain disruptions due to geopolitical events, regulatory changes, or operational issues within the supplier's facilities. However, the company's extensive history of 151 shipments with Elysium Pharmaceuticals Limited suggests a stable and reliable relationship, potentially mitigating some of these risks. The minimal engagement with other suppliers indicates a strategic choice to maintain consistency and quality in its product offerings.

The resilience of Shree Hari International LLC's supply chain is closely tied to the stability and reliability of Elysium Pharmaceuticals Limited. The company's limited number of suppliers and formulations imported suggests a focused approach, which can streamline operations but may also expose the company to risks if alternative suppliers are not readily available. The reliance on a single supplier necessitates a thorough assessment of Elysium Pharmaceuticals Limited's manufacturing capabilities, financial health, and compliance with international quality standards to ensure uninterrupted supply.

Shree Hari International LLC's concentrated sourcing strategy positions it to leverage strong supplier relationships, potentially securing favorable terms and consistent product quality. However, this approach also underscores the importance of supplier diversification to mitigate risks associated with supply chain disruptions. For Indian exporters, the company's focus on a limited number of suppliers presents an opportunity to establish strong partnerships by meeting the specific quality and regulatory standards required by Shree Hari International LLC.

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The Federal Food, Drug, and Cosmetic Act (FD&C Act) provides the legal framework governing these activities, ensuring that imported drugs meet standards for safety, efficacy, and quality. The FDA's regulations require that all drugs offered for importation into the U.S. comply with specific labeling, manufacturing, and testing standards to protect public health.

Importers of pharmaceutical products into the United States must adhere to FDA regulations, which include obtaining appropriate import licenses and ensuring that imported drugs are manufactured in facilities compliant with Good Manufacturing Practice (GMP) standards. The FDA recognizes GMP certifications from various international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications are essential for ensuring that imported pharmaceutical products meet the required quality standards.

Imported pharmaceutical products must undergo batch testing to verify their quality, safety, and efficacy. Stability studies are also required to ensure that products maintain their intended quality throughout their shelf life. Labeling requirements mandate that all drug products offered for importation into the United States include informative and truthful labeling in English, providing consumers with essential information about the product's use, dosage, and potential side effects. Serialization mandates may also apply to facilitate traceability and prevent counterfeit products from entering the supply chain.

Between 2024 and 2026, the FDA has implemented several policy changes affecting the importation of pharmaceutical products from India. These changes include enhanced scrutiny of manufacturing facilities, stricter enforcement of GMP compliance, and updated labeling requirements to improve transparency and consumer safety. Importers like Shree Hari International LLC must stay informed about these regulatory updates to ensure continued compliance and uninterrupted product availability.

Shree Hari International LLC's focus on importing analgesics, antipyretics, respiratory over-the-counter (OTC) medications, and nutritional supplements aligns with prevalent health concerns and consumer demand in the United States. The substantial import value of acetaminophen and phenylephrine indicates a strategic emphasis on products with consistent market demand. This product mix suggests a targeted approach to address common health issues, positioning the company to meet the needs of a broad consumer base.

The company's sourcing strategy centers on generic drug formulations, primarily sourced from India, which is recognized as a major global supplier of affordable pharmaceuticals. By focusing on finished formulations, Shree Hari International LLC ensures that imported products are ready for distribution, streamlining the supply chain and reducing time to market. This approach leverages India's manufacturing capabilities and cost advantages, aligning with the company's objectives to provide cost-effective pharmaceutical options to the U.S. market.

Based on its product mix, Shree Hari International LLC primarily serves the retail pharmacy segment of the U.S. market. The emphasis on OTC medications and widely used therapeutic categories positions the company to supply products that are in high demand among consumers seeking accessible and affordable healthcare solutions. This market positioning enables the company to cater to a broad demographic, including individuals seeking over-the-counter remedies for common ailments.

There is a realistic opportunity for new Indian suppliers to engage with Shree Hari International LLC, particularly those capable of meeting the company's quality standards and regulatory requirements. The company's limited number of suppliers suggests potential gaps in its current sourcing strategy, which new entrants could fill by offering competitive pricing, reliable supply chains, and compliance with FDA regulations. Establishing partnerships with Shree Hari International LLC could provide Indian exporters with access to the U.S. market, leveraging the company's established distribution channels and market knowledge.

Indian exporters seeking to supply Shree Hari International LLC must ensure that their products are manufactured in facilities compliant with recognized GMP standards, such as EU GMP, WHO GMP, or PIC/S certifications. Products must undergo batch testing and stability studies to meet FDA requirements. Additionally, labeling must be informative, truthful, and in English, adhering to FDA regulations. Compliance with these standards is essential for establishing a successful partnership and ensuring the acceptance of products into the U.S. market.

Indian exporters interested in supplying Shree Hari International LLC should initiate contact by providing detailed product information, including specifications, certifications, and compliance with FDA regulations. Participating in industry trade shows and networking events can facilitate relationship-building. Understanding the company's specific product requirements and quality standards is crucial. Developing a clear regulatory filing strategy and understanding the FDA's import procedures will aid in expediting the approval process. Setting realistic timelines for product evaluation, regulatory approval, and market entry is essential for a successful partnership.